Paris pre-opening: 8,000 points, too difficult a milestone for the CAC 40


( — Despite a large part of the session above 8,000 points and a session high of 8,072.31 points, the CAC 40 proved incapable of closing above this symbolic level last night , failing at 7,998.02 points. And this morning the precedence indicators announce a Parisian index still starting below this level, and even moving away from it because it is probably in the red.

ISM manufacturing figures showed yesterday that activity in the United States contracted in May for a second consecutive month, with new orders for goods recording their biggest drop in almost two years. This indicator weighed on the initial optimism of investors, while new economic data will be published this Tuesday such as the Jolts report on job offers in the United States as well as the unemployment rate in Germany.


Wall Street was in disarray on Monday, with the S&P and Nasdaq nevertheless supported by Nvidia following the opening of the ‘Computex 2024’ conference in Taiwan and a keynote by its charismatic boss Jensen Huang. GameStop is also waking up in the wake of “Roaring Kitty” posts on social networks. The S&P 500 rose 0.11% to 5,283 pts, while the Nasdaq gained 0.56% to 16,828 pts. The Dow Jones lost 0.3% to 38,571 pts.



– Orders for durable goods. (4:00 p.m.)
– JOLTS report concerning job openings. (4:00 p.m.)

– Unemployment rate in Germany. (10:00 a.m.)

The euro/dollar parity reached $1.0900 this morning. A barrel of Brent is trading at $77.72. An ounce of gold sells for $2,349.


STMicroelectronics and Geely Auto Group, one of the world’s leading manufacturers of automobiles and new energy vehicles, today announced the signing of a long-term supply agreement for silicon carbide (SiC) components with the aim of accelerate their current cooperation in the field of SiC devices. Under the terms of this multi-year contract, ST will supply several Geely Auto brands with SiC power components for battery electric vehicles.

Sanofi : data from the IMROZ phase III study show that Sarclisa (isatuximab), in combination with bortezomib, lenalidomide and dexamethasone (VRd, reference protocol), followed by the Sarclisa-Rd combination (therapeutic regimen IMROZ), significantly reduced the risk of disease progression or death by 40%, compared to the VRd protocol followed by the Rd combination, in patients with newly diagnosed multiple myeloma, not eligible for transplantation. .

Valbiotis has entered into an agreement with Nestlé Health Science marking the end of the licensing and supply contract between the two companies. The agreement provides for the resumption by Valbiotis on May 31 of all intellectual property rights attached to the license, including in particular: all patents relating to TOTUM 63 in France and internationally (62 countries), as well as the ownership of the clinical data from the REVERSE-IT study and the mode of action study.

Bigben Interactive achieves good performances over the 2023-2024 financial year with clearly improving results. Its turnover over the period amounted to 295 million euros, an increase of +4.1%. Nacon achieved a turnover (non-IFRS) of 170.7 ME, an increase of +9.4% compared to the previous financial year (156 ME). Bigben – Audiovideo/Telco posted activity at €124.3 million, down slightly by -2.5%. The gross margin on turnover benefits from a volume effect and a favorable product mix and gains 4 points to stand at 48.8%. EBITDA stands at €78 million, up +40.8% and represents 26.7% of turnover (19.5% last year). The net result amounts to 21 ME, or 7.2% of turnover (13 ME last year, or 4.6% of turnover).

Wavestone : recurring operating profit amounted to €101.3 million, up +32% compared to the previous financial year, representing a recurring operating margin of 14.5%. On a pro forma basis, established as if the acquisitions of Q_PERIOR and Aspirant Consulting had taken place on April 1, 2023, Wavestone’s 2023/24 turnover stood at €943.8 million. Pro forma recurring operating profit amounted to €123.9 million, representing a recurring operating margin of 13.1%. Net profit amounted to €58.6 million in 2023/24, up +17% compared to the previous year, representing a net margin of 8.4% compared to 9.4% a year earlier. After taking into account minority interests, the group’s net profit stood at €58.2 million in 2023/24. On a pro forma basis, the group’s net profit amounted to €67.7 million in 2023/24.

Kalray announces that it has entered into exclusive negotiations with a view to a merger with the Israeli company Pliops, through the contribution of Pliops shares to Kalray. Pliops specializes in the development of advanced technologies and acceleration solutions for storage servers and AI in data centers.

Airbus: rumors have been multiplying in recent days. The latest comes from China since, according to sources close to the matter cited by ‘Bloomberg’, the European aircraft manufacturer is negotiating a major sale of A330neo to China. The country’s biggest airlines are reportedly considering buying more than 100 next-generation A330 models, according to sources. The terms are still under discussion and the timetable remains uncertain. Talks have reportedly intensified since President Xi Jinping visited his counterpart Emmanuel Macron last month.


Nacon, Catana Group


Goldman Sachs raises its recommendation to “buy” from “neutral” on Eiffage.

HSBC remains a buy on Alstom with a target adjusted to 24 euros.

Bernstein is ‘outperforming’ on Aramis aiming for 9.20 euros. Bernstein is ‘outperforming’ on Michelin with a target of 43 euros.

Stifel remains a buy on Stellantis with a target adjusted to 29 euros.


Medesis Pharma extends its cash horizon

L’Oréal launches its fourth employee shareholding operation

WeAccess: launch of the capital increase


Innate Pharma presents positive results from the TELLOMAK Phase 2 study

Visiativ: details on the proposed sale to Groupe SNEF

Afyren: confident in the continuous start-up of Afyren Neoxy in 2024

Voltalia reaches the milestone of 3 gigawatts of capacity

emeis (formerly Orpea) sells a real estate portfolio of 3 retirement homes in Ireland for €56 million

METabolic EXplorer: a takeover offer for the activities of METEX NØØVISTAGO

Source link -87